The newly approved ipilimumab high-dose adjuvant modality needs to be presented to patients with stage III disease in the upper risk categories for which the trial showed reduction in relapse risk at analysis 18 months ago, as presented to ASCO 2014 and subsequently published. Unfortunately, there i...